Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27488749 | 0.96 | GABRR1 (0.45) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL27488386 | 0.94 | GABRR1 (0.43) | GABRR1CYP1A2BLMACE2ALDH1A1 | |
| SCHEMBL27505821 | 0.91 | GABRR1 (0.48) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL4992239 | 0.80 | ALDH1A1 (0.39) | GABRR1BLMALDH1A1SMN1; SMN2 | |
| SCHEMBL2383663 | 0.78 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7636264 | 0.77 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4368678 | 0.76 | CDC25A (0.40) | CYP1A2ALDH1A1RENACE | |
| SCHEMBL3993608 | 0.76 | ALDH1A1 (0.42) | BLMALDH1A1RENACE | |
| SCHEMBL3997850 | 0.76 | ALDH1A1 (0.42) | BLMALDH1A1RENACE | |
| SCHEMBL4001980 | 0.76 | ALDH1A1 (0.42) | BLMALDH1A1RENACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | claimed |
| CN-101862317-A | The pregabalin derivant that is used for the treatment of fibromyalgia and other disease | WARNER LAMBERT CO | 2010-10-20 | — | — | CN | disclosed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-1310872-C | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726023-A | Pregabalin derivatives for the treatment of fibromyalgia and other diseases | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660779-A | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1196671-C | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | disclosed |